|  | | 
 | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | |
|
| | | 
| |  | |
News Hub Callendar
| < January 2009 | | Su | M | T | W | T | F | S | | | 1 | 2 | 3 |
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
|
| |
|
| | ALTANA continues growth course over the first half-year of 2005 |
|
date: Aug 7th 2005 12:34
page: 1 | 2 | 3 | 4
First-half operating earnings measured in terms of EBITDA totaled €409 million, 11% more than in the prior year, and the EBIT amounted to €347 million, up 12% on the prior year. Earnings before taxes (EBT) added up to €352 million, an increase of 12%. First-half net income totaled €219 million, 15% more than in 2004.
The operating return (EBITDA) in the first half of 2005 was 26.4%, the return on sales before taxes (EBT) amounted to 22.7%. The earnings per share increased by 16% to €1.62.
In the period under review, ALTANA’s capital expenditure on property, plant and equipment and on intangible assets totaled €66 million. The company’s research expenses totaled €216 million. As of June 30, 2005, ALTANA employed for the first time more than 11,000 people worldwide, 3% more than in the first half of 2004. Of the total workforce, about 5,000 were employed in Germany and about 6,000 abroad.
ALTANA Pharma significantly increases sales and earnings
ALTANA Pharma AG, headquartered in Constance, boosted its sales significantly by 9% to €1.1 billion in the first six months of 2005. Sales in the core area of Therapeutics rose by 9% to €981 million. The growth dynamic of the innovative gastrointestinal drug Pantoprazole (Pantozol®/Protonix®) remained unbroken. ALTANA Pharma’s own sales of the drug amounted to €655 million, corresponding to an increase of 8%. Worldwide sales of Pantoprazole by ALTANA Pharma and all sales partners totaled €1.3 billion in the first six months, up by 9%. Sales in the U.S. amounted to US-$863 million, up by 8%. With a share of more than 22% of prescriptions (as of July 1), Pantoprazole’s market position among proton pump inhibitors in the U.S. remains to be strong.
In the first six months ALTANA Pharma was able to increase its earnings before taxes (EBT) by 19% to
page: 1 | 2 | 3 | 4
article 'ALTANA continues growth course over the first half-year of 2005' source is Altana Pharma AG, visit source site:
Articles by information source
News and articles by category
News and articles by day |
|
